Wintermute Biomedical has successfully raised USD 1.3 million from investors to propel its groundbreaking Shingles treatment, Solexan™, into a Phase Ib clinical trial. The primary focus of this randomized double-blind placebo-controlled trial is to assess the safety, tolerability, and proof-of-concept efficacy of Solexan™ in reducing shingles-related pain and expediting lesion healing.
